Stocks / Healthcare

Nautilus Biotechnology Inc

NAUT Stock Report
Current Price
XXXX
Analyst Target Price
$2.50
Market Cap
XXXX
Updated
August 25, 2025
Analysts
4

Nautilus Biotechnology Inc Stock Overview

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a … More details ➜
1 Year Price Range
Low $0.66 Current High $3.09
PinkLion Scores

Fundamentals Summary

P/E Ratio
-
P/S Ratio
-
Net Income
Revenue
Market Cap

Net Income & Revenue

Last Reported Earnings
June 30, 2025
Earnings per share (EPS) $-0.52
Gross Margin -
Net Profit Margin -
Debt/Equity Ratio 2.45%

Dividends

Current Dividend Yield
-
Payout Ratio
-
Forward Dividend Yield
-

Price History

Track historical stock performance, price trends, and volatility for NAUT to see how the stock has performed over time.
YTD
1 Year
5 Years
All

Valuation Summary

We estimate a fair price for NAUT by projecting its future cash flows and discounting them back to today with a XXXXX model.

About the Company

IPO Date
June 10, 2021
Employees
128
Sector
Healthcare
Industry
Biotechnology
Country
USA
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprising instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent probe binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers reagent kits, which include sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.